Piramal Pharma growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−3.1%+7.8%
EBITDA−36.2%+13.6%
Total Assets+14.6%+7.3%
Total Equity+0.5%+6.4%
Free Cash Flow+234.9%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

PPLPHARMA₹230.78

Piramal Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEGLANDWOCKPHARMAASTERDMCOHANCELALPATHLABNATCOPHARMMcap ₹30,628 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-3.1+7.8
EBITDA-36.2+13.6
Total Assets+14.6+7.3
Total Equity+0.5+6.4
Free Cash Flow+234.9—
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.